Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2025
0mins
Source: Globenewswire
Partnership Announcement: Alzamend Neuro has partnered with QMENTA to support five Phase II clinical trials of its drug AL001, aimed at treating Alzheimer’s and other mental health disorders, utilizing QMENTA's AI-driven medical imaging platform for data management and regulatory compliance.
Potential Benefits of AL001: The trials will compare AL001's effectiveness in delivering lithium directly to the brain against traditional lithium carbonate, potentially reducing systemic side effects and eliminating the need for therapeutic drug monitoring, which could improve treatment outcomes for patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
